Tag: Immunotherapy

First-line atezolizumab monotherapy is associated with improved overall survival compared with single-agent chemotherapy

92 percent of 12 patients with refractory immune checkpoint inhibitor-induced colitis achieved clinical remission at end of study

Lack of significant overall survival advantage seen for indefinite-duration versus fixed-duration immunotherapy

Overall and progression-free survival increased for persistent, recurrent, or metastatic cervical cancer

Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer

Significantly more children aged 1 to 3 years receiving epicutaneous immunotherapy had treatment response at 12 months

Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites

Benefits seen in terms of pathologic complete response and event-free survival for resectable non-small cell lung cancer

Black, Hispanic patients have lower rates of initiation than White patients

No toxic effects seen meeting definition of primary end point; profile of toxic effects consistent with that reported in older patients